Intratracheal inoculation of human varicella zoster virus (VZV; MAV strain) vaccine successfully induced VZV IgG antibodies in rhesus monkeys

• Published in: Laboratory animal research 2021, 37(2), , pp.107-111
• Main Authors: Kim, Jong-Min, Park, Chung-Gyu
• Format: Article
• Language: English
• Subjects: Anorexia; Antigens; Asymptomatic; Chicken pox; Epidemics; Fever; Humoral immunity; Immunization; Immunocompetence; Immunoglobulin G; Infections; Inoculation; Laboratory animals; Latent infection; Monkeys & apes; Nonsteroidal anti-inflammatory drugs; Rhesus monkey; Simian varicella virus; Skin; Trachea; Transplantation; Vaccination; Vaccines; Varicella; Varicella-zoster virus; Viruses; Vomiting; 수의학
• ISSN: 2233-7660; 1738-6055; 2233-7660
• DOI: 10.1186/s42826-021-00091-3

Background The objective of this study was to investigate whether the use of live attenuated varicella zoster virus (VZV) MAV vaccination can efficiently induce VZV antibody production in naive rhesus monkeys as an approach to prevent simian varicella virus (SVV) reactivation in animals immunosuppressed for transplantation studies. Results Clinically available human VZV vaccine was used to induce the production of anti-VZV antibodies in rhesus monkeys. A vial of the vaccine was subcutaneously injected at 0 week, and the second and third vaccination was performed at 5 and 6 weeks by intratracheal inoculation. The titer of anti-VZV IgG was assessed at 0, 2, 4, 6, and 7 weeks. At 2 weeks, 3/16 were seropositive for VZV IgG. At 6 weeks, 9/16 were shown to be seropositive. At 7 weeks, 16/16 were found to be seropositive. Conclusions The VZV vaccine via intratrachael inoculation was shown to induce VZV IgG humoral immunity in rhesus monkeys and may be important immunosuppressed macaques for transplantation studies. Although the humoral immunity produced is an important finding, further studies will be necessary to confirm possible protection and it could protect probably against SVV infection in rhesus monkey.